Advertisement
Advice from the leader of Cleveland Clinic Cancer Center
In spite of the challenges posed by the novel coronavirus pandemic, it is essential that patients with suspected, newly diagnosed or progressive cancers receive ongoing care.
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
Cleveland Clinic Cancer Center has continued to provide consultation and treatment during the pandemic, utilizing virtual visits and, when necessary, in-person clinical care with appropriate precautions.
In addition to serving patients in our own healthcare system, the cancer center has connected with oncologists in regions hard-hit by COVID-19 who have had to defer or delay cancer treatments, to offer temporary care until conditions improve and patients can resume seeing their own physicians. (Oncologists in need of this assistance should call Cleveland Clinic’s Cancer Answer Line, 866.223.8100.)
How is it possible to maintain patient services during this difficult time? The key is taking care of the cancer center’s workforce so they can care for others, says Cleveland Clinic Taussig Cancer Institute Chair Brian J. Bolwell, MD. That means addressing fears, sharing information regularly and transparently, and providing the support and encouragement people need to do their jobs.
Learn more about Dr. Bolwell’s approach to leading the cancer center and providing care during COVID-19 by reading his latest column in Oncology Times. In addition to heading Cleveland Clinic Cancer Center, Dr. Bolwell is Cleveland Clinic’s Director of Physician Leadership and Development.
Advertisement
Advertisement
Cleveland Clinic Cancer Institute among select group of centers to administer highly personalized treatment
Real-world results reporting aims to make treatments safer and more effective
Ongoing clinical validation in diverse populations refine breast cancer risk substratification
Soft tissue pathologist discusses research into incorporating genomic data to improve risk stratification
Prediction and bioinformatic data could prove valuable for therapeutic interventions targeting this malignancy
Phase 3 trial found no survival differences between weekly or biweekly doxorubicin/cyclophosphamide or between weekly or biweekly paclitaxel
Findings strengthen evidence for risk-reducing procedures
Offers a new option for patients 60 and older with relapsed/refractory disease